Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

SECUKINUMAB vs SELADELPAR LYSINE: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

SECUKINUMAB vs SELADELPAR LYSINE: Safety Overview

Metric SECUKINUMAB SELADELPAR LYSINE
Total FAERS Reports 151,223 107
Deaths Reported 6,855 1
Death Rate 4.5% 0.9%
Hospitalizations 19,098 4
Average Patient Age 52.3 yrs 61.5 yrs
% Female Patients 61.9% 94.3%
FDA Approval Date N/A Aug 14, 2024
Manufacturer Novartis Pharmaceuticals Corporation Gilead Sciences, Inc
Route SUBCUTANEOUS ORAL
Marketing Status Prescription Prescription